Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telmisartan + hydrochlorothiazide (Dios Lifesciences)
- Development stage
- Unknown
- Lead developer
- Dios Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vintel-40H is a fixed-dose combination pharmaceutical product containing telmisartan and hydrochlorothiazide. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubules of the kidney, leading to increased excretion of water and electrolytes. Marketed by Dios Lifesciences, Vintel-40H is indicated for the treatment of hypertension, particularly in patients whose blood pressure is not adequately controlled by telmisartan monotherapy.
- Brand names
- Vintel-40HVintel40HVintel 40H
- Other names
- Telmisartan/Hydrochlorothiazide 40mg/12.5mg
02
Targets
SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)PPARG (Peroxisome proliferator-activated receptor gamma)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on telmisartan + hydrochlorothiazide (Dios Lifesciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telmisartan + hydrochlorothiazide (Dios Lifesciences).